SecBot SecBot
SECBOTREPLAY Home › Report › IONS

IONS · Ionis reported Q2 2026 total revenue of $268M, up 56% YoY excluding a…

IONIS PHARMACEUTICALS INC · 8-K filed Jul 29, 2026 at 07:31 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Jul 29, 2026 at 07:31 ET

Ionis reported Q2 2026 total revenue of $268M, up 56% YoY excluding a one-time 2025 sapablursen payment, but GAAP net loss widened to $115M from a $124M profit in Q2 2025 which included a $280M upfront. Commercial revenue grew 15% YoY driven by DAWNZERA ($26M, +63% QoQ) and early TRYNGOLZA sHTG launch momentum. The company maintained full-year 2026 guidance and reiterated its 2028 cash-flow breakeven target.

  • Q2 2026 total revenue $268M vs $452M in Q2 2025 (Q2 2025 included $280M sapablursen upfront); ex that item, revenue +56% YoY
  • Non-GAAP net loss $70M vs non-GAAP net income $154M in Q2 2025
  • TRYNGOLZA net product sales $5M in Q2, $32M H1; on track for full-year $100-110M guidance
  • DAWNZERA net product sales $26M in Q2, +63% QoQ; on track for full-year $110-120M guidance

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access